Lumizyme®

Understanding Lumizyme® 

Lumizyme® (alglucosidase alfa) is an enzyme replacement therapy (ERT) used to treat Pompe disease, a rare genetic disorder caused by a deficiency of the enzyme acid alpha-glucosidase (GAA). This enzyme is essential for breaking down glycogen in muscle cells. Without enough GAA, glycogen accumulates in muscles, leading to progressive muscle weakness, respiratory issues, and reduced mobility. Lumizyme® helps replace the missing enzyme, slowing disease progression and improving muscle function.

How Lumizyme® Works:

• Replaces the missing acid alpha-glucosidase (GAA) enzyme, helping break down glycogen.
• Reduces glycogen buildup in muscle cells, preventing further damage.
• Improves muscle strength and respiratory function, helping maintain mobility and quality of life.

FDA Approval:

• May 24, 2010 – Approved for the treatment of Pompe disease.

For more information, please visit the Lumizyme® patient website and speak with your healthcare provider to determine if Lumizyme® is the right treatment option for you.